Dr. Reddy’s Laboratories Ltd. has got approval to conduct second and third phase human trials of the Kovid-19 vaccine Sputnik V in India. The company gave its information in a statement. The company said that it and the Russian Direct Investment Fund (RDIF) have received this approval from the Comptroller General of India (DGCI). The company said that it will be a controlled study, which will be done at many centers.
Earlier in September 2020, Dr. Reddy’s and RDIF partnered to test the Sputnik V vaccine and its distribution in India.
Also read- 3428 new cases of Kovid-19 were reported in Delhi, 22 people died
Under the partnership, RDIF will supply 10 million doses of the vaccine to Dr. Reddy’s in India on regulatory approval.
Also read- Corona cases cross 74 lakhs in the country, active cases reduced by 8 lakhs
Company co-chairman and managing director GV Prasad said, “This is important news, which allows us to start clinical trials in India. We are committed to bringing a safe and effective vaccine to combat the epidemic.”
Also read- PM Modi said – India is fighting an important war against malnutrition even during the Corona era
RDIF Chief Executive Officer (CEO) Kirill Damitriyev said, “We are pleased to collaborate with Indian regulators. We will share the data of the Phase III trial in Russia as well as the trial to be conducted in India. Will help in development.
Ravish Kumar’s prime time: why careless about Corona?
(This news has not been edited by the NewsBust team. It is published directly from the Syndicate feed.)